Global Markets Lifted as Data-Center Deals Accelerate

Capital is concentrating around artificial intelligence, digital infrastructure, quantum computing, and targeted healthcare platforms as investors assess fresh corporate announcements and market signals published on October 12. At a glance: European equity futures moved higher while oil prices declined in morning trading, according to Morningstar’s EMEA market briefing. The day’s corporate flow also showed technology and healthcare companies using acquisitions and partnerships to secure specialized capabilities rather than relying solely on internal development. LG Electronics agreed to acquire a stake in French quantum-computing developer Pasqal, while Qatar Investment Authority and Blue Owl Capital advanced a digital-infrastructure platform built around more than $3 billion of data-center assets. In healthcare, Valerio Therapeutics completed its acquisition of Etherna Immunotherapies, creating an integrated targeted-RNA platform. The announcements reinforce a market preference for assets linked to computing capacity, cybersecurity, artificial intelligence, and precision medicine. They also provide investors with fresh evidence that strategic capital remains active across transatlantic and Asia-Pacific technology corridors, even as broader market positioning continues to respond to movements in energy prices and equity futures.

Technology advance: e.l.f. Cosmetics launched “Express Your e.l.f.,” its first virtual styling experience on ZEPETO, an avatar-based social platform. The Oakland, California-based beauty company is bringing product discovery and digital self-expression into an immersive environment where users can create and share customized avatars. The launch represents a commercial technology initiative rather than a conventional physical-product release, extending e.l.f. Beauty’s consumer engagement strategy into social and virtual spaces. The experience gives the company a new channel for brand interaction and may help connect cosmetics marketing with creator-driven digital communities. Separately, FPT and NAVER Cloud signed a memorandum of understanding to expand their AI Factory business across Asia-Pacific and global markets. Their cooperation covers joint technology development, AI service delivery, and commercialization initiatives. The agreement links Vietnam’s FPT with South Korea’s NAVER Cloud and places regional AI deployment, enterprise services, and cross-border commercialization at the center of the latest technology expansion activity.

Partnerships: Qatar Investment Authority and Blue Owl Capital agreed to create a digital-infrastructure platform focused on data centers, combining assets valued at more than $3 billion. QIA is expected to provide an initial $1 billion investment, forming the foundation for additional capital raising and further expansion of computing and data-storage capacity. The arrangement reflects the increasing role of sovereign wealth funds in financing infrastructure required by cloud services, artificial intelligence, and high-performance computing. Rather than focusing on a single facility, the platform is designed to consolidate and expand a broader data-center portfolio. The partnership also gives Blue Owl a large institutional capital partner while providing QIA with exposure to an infrastructure segment benefiting from persistent demand for power, connectivity, and storage. For investors, the agreement highlights the scale of capital now being directed toward physical assets supporting digital businesses and the growing overlap between private markets, sovereign investment, and technology infrastructure.

Acquisitions/expansions: Valerio Therapeutics completed its acquisition of 100% of Etherna Immunotherapies’ share capital and voting rights. The French biotechnology company said the transaction builds an integrated targeted-RNA platform intended to accelerate progress toward clinical development. Etherna brings capabilities associated with immunotherapies and RNA-based approaches, while Valerio contributes its precision-guided RNA focus. Completion of the transaction gives Valerio control of the acquired business rather than merely establishing a research collaboration, allowing the company to align scientific programs, intellectual property, and development resources under one corporate structure. The deal is significant for investors tracking biotechnology consolidation because it illustrates how smaller firms are combining complementary RNA technologies to create more complete therapeutic platforms. The acquisition also increases Valerio’s strategic emphasis on targeted medicines and may broaden the range of programs that can be advanced toward clinical testing, subject to development and regulatory requirements.

Regulatory/policy: Foresee Pharmaceuticals announced that China’s National Medical Products Administration approved CAMCEVI 42 mg for advanced prostate cancer. Changchun GeneScience Pharmaceutical will commercialize the treatment in China, creating a defined regulatory and distribution pathway in one of the world’s largest pharmaceutical markets. The approval is a concrete market-access event rather than a development-stage update, because it allows the product to move into commercialization activities subject to local requirements. For Foresee, the decision supports international expansion of its oncology portfolio and gives the company a regional commercialization partner with responsibility for the Chinese market. The announcement also illustrates how regulatory decisions can reshape biotech valuation by converting clinical and manufacturing investment into potential commercial revenue. Investors will focus on the timing of launch activities, the scale of the addressable prostate-cancer market, and the commercial execution of Changchun GeneScience as the product moves from approval toward availability in China.

Finance/business: IBM completed its acquisition of Hakkoda, a data-processing and artificial-intelligence consulting company. Hakkoda specializes in migrating, modernizing, and monetizing data warehouses and is a partner of Snowflake, strengthening IBM’s ability to support enterprise data transformation and AI initiatives. The transaction adds consulting expertise in areas that companies increasingly need before deploying advanced AI systems: data architecture, cloud migration, governance, and operationalization. IBM’s purchase positions Hakkoda’s capabilities within a larger services portfolio and expands the company’s ability to connect data modernization with AI implementation. The deal also reflects continuing investor attention to acquisitions that generate enterprise-software and consulting capacity without depending exclusively on speculative consumer demand. Alongside the day’s infrastructure and biotechnology transactions, IBM’s move indicates that corporate buyers are still allocating capital toward specialized platforms that can support recurring technology spending, improve customer adoption, and capture demand created by the rapid expansion of artificial-intelligence workloads.

Sources: Morningstar, Business Wire, AK&M, The Quantum Insider